The Therapeutic Effect of EZH2 Inhibitors in Targeting Human Papillomavirus Associated Cervical Cancer.

ABSTRACT: High-risk human papillomavirus (HPV) is a crucial risk factor in the development of cervical cancer, where epigenetic modifications and epithelial-mesenchymal transition (EMT) processes have been implicated in cancer progression and metastasis. Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is frequently overexpressed in HPV-associated cervical cancers and has been linked to tumour progression. However, there is still no consensus on the mechanisms of their action and their effectiveness on HPV-associated cancers. This study aimed to investigate whether EZH2 inhibitors (EPZ6438 and ZLD1039) can be effective in managing cervical cancer with less toxic effects than the conventional chemotherapeutic drug cisplatin. Proliferation assay and flow cytometry results showed that E

SUBMITTER: Vidalina D 

PROVIDER: S-EPMC12732196 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature